Annual accounts receivable:
$79.07M+$22.12M(+38.84%)Summary
- As of today (September 5, 2025), BCRX annual accounts receivable is $79.07 million, with the most recent change of +$22.12 million (+38.84%) on December 31, 2024.
- During the last 3 years, BCRX annual accounts receivable has risen by +$49.66 million (+168.82%).
- BCRX annual accounts receivable is now at all-time high.
Performance
BCRX Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$91.18M-$2.22M(-2.37%)Summary
- As of today (September 5, 2025), BCRX quarterly accounts receivable is $91.18 million, with the most recent change of -$2.22 million (-2.37%) on June 30, 2025.
- Over the past year, BCRX quarterly accounts receivable has increased by +$22.42 million (+32.60%).
- BCRX quarterly accounts receivable is now -2.37% below its all-time high of $93.39 million, reached on March 31, 2025.
Performance
BCRX Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
BCRX Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +38.8% | +32.6% |
| 3 y3 years | +168.8% | +119.8% |
| 5 y5 years | +257.0% | +2181.1% |
BCRX Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +168.8% | -2.4% | +119.8% |
| 5 y | 5-year | at high | +814.5% | -2.4% | +2181.1% |
| alltime | all time | at high | >+9999.0% | -2.4% | >+9999.0% |
BCRX Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $91.18M(-2.4%) |
| Mar 2025 | - | $93.39M(+18.1%) |
| Dec 2024 | $79.07M(+38.8%) | $79.07M(+9.1%) |
| Sep 2024 | - | $72.46M(+5.4%) |
| Jun 2024 | - | $68.76M(+13.5%) |
| Mar 2024 | - | $60.59M(+6.4%) |
| Dec 2023 | $56.95M(+12.6%) | $56.95M(+6.2%) |
| Sep 2023 | - | $53.65M(-7.0%) |
| Jun 2023 | - | $57.67M(+18.6%) |
| Mar 2023 | - | $48.64M(-3.9%) |
| Dec 2022 | $50.60M(+72.0%) | $50.60M(+18.7%) |
| Sep 2022 | - | $42.61M(+2.7%) |
| Jun 2022 | - | $41.49M(+13.9%) |
| Mar 2022 | - | $36.41M(+23.8%) |
| Dec 2021 | $29.41M(+240.2%) | $29.41M(+12.2%) |
| Sep 2021 | - | $26.21M(-5.1%) |
| Jun 2021 | - | $27.62M(+50.2%) |
| Mar 2021 | - | $18.39M(+112.7%) |
| Dec 2020 | $8.65M(-61.0%) | $8.65M(+59.5%) |
| Sep 2020 | - | $5.42M(+35.7%) |
| Jun 2020 | - | $4.00M(-29.2%) |
| Mar 2020 | - | $5.64M(-74.5%) |
| Dec 2019 | $22.15M(+415.9%) | $22.15M(+515.5%) |
| Sep 2019 | - | $3.60M(-0.1%) |
| Jun 2019 | - | $3.60M(-28.0%) |
| Mar 2019 | - | $5.00M(+16.5%) |
| Dec 2018 | $4.29M(-29.8%) | $4.29M(+26.5%) |
| Sep 2018 | - | $3.39M(+44.9%) |
| Jun 2018 | - | $2.34M(-58.9%) |
| Mar 2018 | - | $5.69M(-6.9%) |
| Dec 2017 | $6.12M(-30.2%) | $6.12M(-31.9%) |
| Sep 2017 | - | $8.98M(+170.2%) |
| Jun 2017 | - | $3.33M(-65.2%) |
| Mar 2017 | - | $9.56M(+9.1%) |
| Dec 2016 | $8.77M(+40.4%) | $8.77M(+46.9%) |
| Sep 2016 | - | $5.97M(+167.1%) |
| Jun 2016 | - | $2.23M(-69.7%) |
| Mar 2016 | - | $7.38M(+18.3%) |
| Dec 2015 | $6.24M | $6.24M(-16.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2015 | - | $7.50M(+74.5%) |
| Jun 2015 | - | $4.30M(-23.2%) |
| Mar 2015 | - | $5.59M(-16.7%) |
| Dec 2014 | $6.71M(+217.4%) | $6.71M(+107.3%) |
| Sep 2014 | - | $3.24M(+261.0%) |
| Jun 2014 | - | $897.00K(-72.7%) |
| Mar 2014 | - | $3.28M(+55.1%) |
| Dec 2013 | $2.12M(-53.6%) | $2.12M(-10.7%) |
| Sep 2013 | - | $2.37M(+131.3%) |
| Jun 2013 | - | $1.02M(-76.3%) |
| Mar 2013 | - | $4.33M(-5.2%) |
| Dec 2012 | $4.56M(-21.8%) | $4.56M(+21.1%) |
| Sep 2012 | - | $3.77M(-25.9%) |
| Jun 2012 | - | $5.08M(-13.1%) |
| Mar 2012 | - | $5.85M(+0.4%) |
| Dec 2011 | $5.83M(-80.7%) | $5.83M(-49.9%) |
| Sep 2011 | - | $11.63M(-27.1%) |
| Jun 2011 | - | $15.96M(-38.8%) |
| Mar 2011 | - | $26.06M(-13.8%) |
| Dec 2010 | $30.23M(-10.4%) | $30.23M(+130.7%) |
| Dec 2009 | $33.72M(+181.4%) | - |
| Dec 2008 | $11.98M(>+9900.0%) | - |
| Sep 2008 | - | $13.10M(-11.8%) |
| Jun 2008 | - | $14.85M(-48.0%) |
| Mar 2008 | - | $28.58M(-27.0%) |
| Dec 2007 | - | $39.13M(+88.6%) |
| Sep 2007 | - | $20.75M(+13.5%) |
| Jun 2007 | - | $18.27M(+118.4%) |
| Mar 2007 | - | $8.37M(+83.6%) |
| Dec 2006 | - | $4.56M(+45.1%) |
| Sep 2006 | - | $3.14M(+58.9%) |
| Jun 2006 | - | $1.98M(+213.5%) |
| Mar 2006 | - | $630.00K(-97.9%) |
| Dec 2005 | - | $30.00M |
| Dec 1999 | $0.00(0.0%) | - |
| Dec 1998 | $0.00(0.0%) | - |
| Dec 1997 | $0.00(0.0%) | - |
| Dec 1996 | $0.00(0.0%) | - |
| Dec 1995 | $0.00(0.0%) | - |
| Dec 1994 | $0.00 | - |
FAQ
- What is BioCryst Pharmaceuticals, Inc. annual accounts receivable?
- What is the all time high annual accounts receivable for BioCryst Pharmaceuticals, Inc.?
- What is BioCryst Pharmaceuticals, Inc. annual accounts receivable year-on-year change?
- What is BioCryst Pharmaceuticals, Inc. quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for BioCryst Pharmaceuticals, Inc.?
- What is BioCryst Pharmaceuticals, Inc. quarterly accounts receivable year-on-year change?
What is BioCryst Pharmaceuticals, Inc. annual accounts receivable?
The current annual accounts receivable of BCRX is $79.07M
What is the all time high annual accounts receivable for BioCryst Pharmaceuticals, Inc.?
BioCryst Pharmaceuticals, Inc. all-time high annual accounts receivable is $79.07M
What is BioCryst Pharmaceuticals, Inc. annual accounts receivable year-on-year change?
Over the past year, BCRX annual accounts receivable has changed by +$22.12M (+38.84%)
What is BioCryst Pharmaceuticals, Inc. quarterly accounts receivable?
The current quarterly accounts receivable of BCRX is $91.18M
What is the all time high quarterly accounts receivable for BioCryst Pharmaceuticals, Inc.?
BioCryst Pharmaceuticals, Inc. all-time high quarterly accounts receivable is $93.39M
What is BioCryst Pharmaceuticals, Inc. quarterly accounts receivable year-on-year change?
Over the past year, BCRX quarterly accounts receivable has changed by +$22.42M (+32.60%)